23 November 2017
News and Views
Links and Services
This week's issue of the Lancet evaluates adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumors.
Gastrointestinal (GI) stromal tumor is the most common sarcoma of the intestinal tract.
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors